CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 120 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $901,589 | -19.3% | 698,906 | +7.6% | 0.00% | -100.0% |
| Q2 2023 | $1,116,793 | +76867.1% | 649,298 | -32.4% | 0.00% | 0.0% |
| Q1 2023 | $1,451 | -47.3% | 961,042 | -44.1% | 0.00% | -50.0% |
| Q4 2022 | $2,752 | -99.6% | 1,719,811 | +223.0% | 0.00% | – |
| Q3 2022 | $772,000 | -70.7% | 532,513 | -63.1% | 0.00% | -100.0% |
| Q2 2022 | $2,638,000 | -56.0% | 1,441,732 | -35.8% | 0.00% | -33.3% |
| Q1 2022 | $5,995,000 | +9.3% | 2,245,190 | +77.2% | 0.00% | 0.0% |
| Q4 2021 | $5,486,000 | +15.0% | 1,266,922 | +35.2% | 0.00% | 0.0% |
| Q3 2021 | $4,769,000 | +26.3% | 936,848 | +57.1% | 0.00% | +50.0% |
| Q2 2021 | $3,775,000 | -6.7% | 596,329 | +14.0% | 0.00% | -33.3% |
| Q1 2021 | $4,045,000 | +70.3% | 523,242 | +44.3% | 0.00% | +50.0% |
| Q4 2020 | $2,375,000 | +20.4% | 362,661 | +22.3% | 0.00% | 0.0% |
| Q3 2020 | $1,972,000 | +123.3% | 296,614 | +179.8% | 0.00% | +100.0% |
| Q2 2020 | $883,000 | -60.9% | 106,022 | -64.0% | 0.00% | -80.0% |
| Q1 2020 | $2,257,000 | -16.2% | 294,313 | -9.2% | 0.01% | +66.7% |
| Q4 2019 | $2,692,000 | +477.7% | 323,982 | +412.0% | 0.00% | +200.0% |
| Q3 2019 | $466,000 | -91.3% | 63,273 | -86.7% | 0.00% | -87.5% |
| Q2 2019 | $5,328,000 | +451.0% | 474,838 | +428.0% | 0.01% | +700.0% |
| Q1 2019 | $967,000 | -59.6% | 89,937 | -43.2% | 0.00% | -75.0% |
| Q4 2018 | $2,392,000 | -40.6% | 158,438 | -27.2% | 0.00% | -20.0% |
| Q3 2018 | $4,024,000 | -33.6% | 217,491 | -17.9% | 0.01% | -37.5% |
| Q2 2018 | $6,056,000 | -64.2% | 264,921 | -55.5% | 0.01% | -65.2% |
| Q1 2018 | $16,922,000 | -4.3% | 594,788 | -29.0% | 0.02% | -4.2% |
| Q4 2017 | $17,678,000 | +55.7% | 837,415 | +34.0% | 0.02% | +41.2% |
| Q3 2017 | $11,356,000 | +614.7% | 624,992 | +509.8% | 0.02% | +466.7% |
| Q2 2017 | $1,589,000 | -45.1% | 102,497 | -38.9% | 0.00% | -40.0% |
| Q1 2017 | $2,896,000 | +392.5% | 167,690 | +213.6% | 0.01% | +400.0% |
| Q4 2016 | $588,000 | +305.5% | 53,470 | +276.7% | 0.00% | – |
| Q2 2016 | $145,000 | – | 14,195 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |